Treatment

IDO1 inhibitor clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
This study looks at new ways to treat advanced cancers using a combination of different medications. Researchers want to see how safe these combinations are and how well they work to shrink tumours or stop them from growing.
For: Advanced Malignant Tumors
Italy · France · Spain